Page 156 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition edition
Guidelines for the treatment of malaria – 2 nd
importance CRITICAL IMPORTANT IMPORTANT IMPORTANT IMPORTANT

Quality VERY LOW VERY LOW VERY LOW MODERATE
–
7 fewer per 1000 (from 12 fewer to 1 more)

Absolute Not pooled Not pooled Not pooled –

effect Relative risk (95% CI) Not pooled Not pooled 13/346 (3.8%)Not pooled RR 0.61 (0.36–1.03) –

Is AS+AQ superior to AQ+SP for treating uncomplicated P. falciparum malaria in Africa?
summary of findings no. of patients AQ + SP AS + AQ 136/1020 73/1137 (13.3%) (6.4%) 718/1888 635/2089 (38%) (30.4%) 8/548 (1.5%) 35/1944 20/2116 (1.8%) (0.9%) – –

considerations

Other None None None None –

Imprecision Very serious 5 Very serious 5 Very serious 5 Serious 10 –

Indirectness No serious indirectness 4 No serious indirectness 4 No serious indirectness 4 No serious indirectness 4 –

Inconsistency Serious 3 Serious 7 Serious 7 No serious inconsistency 9

Limitations No serious limitations 2 No serious limitations 6 No serious limitations 8 No serious limitations 6 –

GRADE Table A7.1.4 Quality assessment Design EFFICACy: total failure (P. falciparum) day 28 PCR adjusted Randomized trial 1 EFFICACy: total failure (P . falciparum) day 28 PCR unadjusted Randomized trial TRANSMISSION POTENTIAL: gametocyte carriage day 14 Randomized trial HARMS: serious adverse events (including deaths) Randomized t

142 No. of studies 5 7 3 7 0